Drug intelligence / Profile preview

BT1

Development stage: Preclinical
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BT1 is an Fc-null T-cell engager designed to target CD84, a protein highly expressed on acute myeloid leukemia (AML) blasts and enriched on leukemic stem cells (LSCs). By binding to CD84 on AML cells, BT1 recruits T-cells to induce potent and selective killing of AML cell lines and primary AML blasts. It has demonstrated the ability to abrogate the clonogenic capacity of primary AML blasts and significantly extend survival in xenograft models, supporting its potential as a novel immunotherapeutic for AML.

Targets

SLAMF5 (Signaling lymphocyte activation molecule family member 5)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on BT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT1.

Explore the full profile